On July 8, 20221 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in one-on-one investor meetings and Chief Science Officer, Takashi Kei Kishimoto, Ph.D., will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 to be held virtually, July 14-15 (Press release, Selecta Biosciences, JUL 8, 2021, View Source [SID1234584709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the panel can be found below.

Title: Delivery and Durability of Genetic Medicines
Date & Time: Thursday, July 15 at 10:00 a.m. ET